-

ACI Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Albertsons Companies (ACI)

Albertsons shareholders who lost money after the July 23, 2026 FY 2026 guidance cut may have rights. Levi & Korsinsky is reviewing the April guidance and the sharply lower July update.

NEW YORK--(BUSINESS WIRE)--A 22% drop hit Albertsons Companies (NYSE: ACI) shares on July 23, 2026, after the Company cut FY 2026 adjusted EPS guidance to $1.75-$1.85 from $2.22-$2.32. Investors who held ACI through the guidance cut and suffered losses should act promptly. ACI shareholders who lost money are encouraged to submit their loss details now or contact Levi & Korsinsky, LLP | (212) 363-7500 | www.zlk.com

On April 14, 2026, CFO Sharon McCollam told investors that adjusted EPS was expected “to be in the range of $2.22 to $2.32,” including approximately $600 million of share repurchases. CEO Susan Morris stated that Albertsons was entering fiscal 2026 from a position of “confidence, clarity and momentum.” The July 23 update cut the adjusted EPS range by roughly 20% at the midpoint.

Albertsons’ April 27, 2026 Form 10-K identified pharmacy reimbursement pressure, the potential impacts of the Inflation Reduction Act and macroeconomic uncertainty as material risks to the Company’s business and financial performance. After the July 23 reduction, Levi & Korsinsky is investigating potential securities law violations connected to the Company’s FY 2026 guidance and the timing of the lower outlook. The investigation focuses on investors who lost money in the July 23 decline.

If you suffered losses in Albertsons shares after the FY 2026 guidance cut, send us your ACI loss information or call (212) 363-7500.

Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com

Frequently Asked Questions About the ACI Investigation

Q: Which statements are being reviewed in the ACI investigation? A: The investigation concerns Albertsons Companies’ April 14, 2026 FY 2026 adjusted EPS guidance of $2.22 to $2.32 and the July 23, 2026 reduction to $1.75 to $1.85. ACI shares fell approximately 22% after the reduced outlook was released.

Q: When did Albertsons allegedly mislead investors? A: The investigation concerns statements made before the July 23, 2026 guidance reduction, including public comments about the Company’s fiscal 2026 outlook.

Q: Who is eligible to participate in the ACI investigation? A: Investors who purchased ACI stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What should ACI investors do right now? A: Gather brokerage records, including purchase dates, share quantities, and prices paid. Keep records showing any sale dates, sale prices, and total losses.

Q: What if I already sold my ACI shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ACI and sold at a loss may still participate in the investigation.

Q: What if my ACI losses are small -- is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting proceedings are generally handled on a contingency basis, with no upfront fees, no retainer, and no out-of-pocket costs.

Attorney Advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NYSE:ACI

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)

NEW YORK--(BUSINESS WIRE)--On July 24, 2026, Zevra Therapeutics (NASDAQ: ZVRA) shares fell approximately 24% after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease type C. Investors who suffered losses tied to the ZVRA drop are encouraged to submit your loss information now or contact Levi & Korsinsky, LLP | (212) 363-7500 | www.zlk.c...

ADTN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into ADTRAN Holdings (ADTN)

NEW YORK--(BUSINESS WIRE)--ADTRAN Holdings (NASDAQ: ADTN) shares fell approximately 15% on July 22, 2026 after the company announced preliminary unaudited Q2 2026 revenue of $280 million to $282 million and non-GAAP operating margin of about 3.5% to 4.0%, both below its guidance of $283 million to $303 million in revenue and 5% to 9% non-GAAP operating margin. If this decline hit your ADTN investment, you are encouraged to submit your information now. You may also contact Joseph E. Levi, Esq. a...

RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy’s Laboratories (RDY)

NEW YORK--(BUSINESS WIRE)--RDY shareholders saw Dr. Reddy’s Laboratories (NYSE: RDY) shares fall approximately 9% on July 22, 2026, after Q1 FY27 results included a ₹2.4 billion provision tied to out-of-spec semaglutide batches while FY27 margin commentary remained in focus. Investors who lost money on RDY after that provision disclosure are encouraged to act now. Levi & Korsinsky is investigating potential securities law violations involving Dr. Reddy’s forward-looking profitability stateme...
Back to Newsroom